Characteristics and treatment patterns of patients with Obstructive Sleep Apnea (OSA) initiating Positive Airway Pressure (PAP) therapy

First published: 23/01/2023

Last updated: 23/04/2024





Administrative details

EU PAS number	
EUPAS49842	
Study ID	
49843	
DARWIN EU® study	
No	
Study countries	
United States	
States	

Study description

There is a lack of comprehensive assessment about the processes involved for OSA patients, from sleep test, diagnosis, utilization of PAP, and their overall related health care service utilization. This study aims to examine OSA patients' adherence to PAP treatments, along with assessing their health care resource utilization (HCRU) and associated costs. Additionally, the study aims to explore the patient journey through different stages from the initial sleep test to being prescribed PAP treatment.

Study status

Planned

Research institutions and networks

Institutions

HealthCore

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Haynes Aaron ahaynes@healthcore.com

Study contact

ahaynes@healthcore.com

Primary lead investigator

Karishma Desai

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 08/08/2022

Actual: 08/08/2022

Study start date

Planned: 12/01/2022

Date of final study report

Planned: 28/07/2023

Sources of funding

• Pharmaceutical company and other private sector

More details on funding

Eli Lilly

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Other

If 'other', further details on the scope of the study

Treatment Exposure

Main study objective:

To examine initiation, short-term (6 months), and long-term (12 and 24 months) adherence patterns to positive airway pressure (PAP) therapy among commercially insured and managed Medicare US patients with obstructive sleep apnea (OSA).

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Medical condition to be studied

Obstructive sleep apnoea syndrome

Population studied

Age groups

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

Estimated number of subjects

391272

Study design details

Data analysis plan

Descriptive statistics including means and standard deviations for continuous variables and frequencies for categorical values will be computed for all baseline variables including demographics, clinical characteristics, and SDOH data for the overall sample population.

Documents

Study results

ELI_SLEEP_PAP_48x48_2023 Poster_sv3.pdf (490.02 KB)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

Administrative healthcare records (e.g., claims)

Drug dispensing/prescription data

Other

Data sources (types), other

Prescription event monitoring

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No